posted on 2020-10-21, 17:45authored byAda AdminAda Admin, Kuntol Rakshit, Aleksey V. Matveyenko
Type 2 diabetes mellitus (T2DM) is characterized by β cell dysfunction due to impaired
glucose-stimulated insulin secretion (GSIS). Studies show that β cell circadian
clocks are important regulators of GSIS and glucose homeostasis. These
observations raise the question whether enhancement of the circadian clock in β cells will
confer protection
against β cell dysfunction under diabetogenic conditions. To
test this we employed an approach by first generating mice with β cell-specific
inducible overexpression of Bmal1 (core
circadian transcription factor; β-Bmal1OV). We subsequently
examined the effects of β-Bmal1OVon the circadian clock, GSIS, islet transcriptome, and glucose metabolism
in context of diet-induced obesity. We additionally tested the effects of circadian
clock-enhancing small molecule Nobiletin on GSIS in mouse and human control and
T2DM islets. We report that β-Bmal1OVmice displayenhanced islet
circadian clock amplitude, augmented in
vivo and in vitro GSIS and are
protected against obesity-induced glucose intolerance. These effects were associated
with increased expression of purported BMAL1-target genes mediating insulin
secretion, processing, and lipid metabolism. Furthermore, exposure of isolated
islets to Nobiletin enhanced β cell secretory function in Bmal1-dependent manner. This work suggests therapeutic targeting of
the circadian system as a potential strategy to counteract β cell failure under
diabetogenic conditions.
Funding
We acknowledge funding support from the National Institutes of Health (2R01DK098468 to AVM) and the Center for Regenerative Medicine (Mayo Clinic, Rochester, MN).